In BRAFV600E-mutated colorectal cancers, the combination treatment of BRAF inhibitor encorafenib and anti-EGFR monoclonal antibody cetuximab has shown positive results in a phase III BEACON trial and became the standard second-/third-line treatment for these cancers [101]. The gene discussed is BRAF; the disease is cancer.